• Jemily Malvar, Florin Vaida, Chelsea Fitzsimons Sanders, J Hampton Atkinson, William Bohannon, John Keltner, Jessica Robinson-Papp, David M Simpson, Christina M Marra, David B Clifford, Benjamin Gelman, Juanjuan Fan, Igor Grant, Ronald J Ellis, and CHARTER Group.
• Children's Hospital, Los Angeles, CA, USA HIV Neurobehavioral Research Program, University of California, San Diego, CA, USA Icahn School of Medicine at Mount Sinai, New York, NY University of Washington, Seattle, WA, USA Washington University, St Louis, MO, USA University of Texas Medical Branch, Galveston, TX San Diego State University, San Diego, CA Alliant International University, San Diego, CA.
• Pain. 2015 Apr 1; 156 (4): 731739731-739.

AbstractDespite modern combination antiretroviral therapy, distal neuropathic pain (DNP) continues to affect many individuals with HIV infection. We evaluated risk factors for new-onset DNP in the CNS Antiretroviral Therapy Effects Research (CHARTER) study, an observational cohort. Standardized, semiannual clinical evaluations were administered at 6 US sites. Distal neuropathic pain was defined by using a clinician-administered instrument standardized across sites. All participants analyzed were free of DNP at study entry. New-onset DNP was recorded at the first follow-up visit at which it was reported. Mixed-effects logistic regression was used to evaluate potential predictors including HIV disease and treatment factors, demographics, medical comorbidities, and neuropsychiatric factors. Among 493 participants, 131 (27%) reported new DNP over 2306 visits during a median follow-up of 24 months (interquartile range 12-42). In multivariable regression, after adjusting for other covariates, significant entry predictors of new DNP were older age, female sex, current and past antiretroviral treatment, lack of virologic suppression, and lifetime history of opioid use disorder. During follow-up, more severe depression symptoms conferred a significantly elevated risk. The associations with opioid use disorders and depression reinforce the view that the clinical expression of neuropathic pain with peripheral nerve disease is strongly influenced by neuropsychiatric factors. Delineating such risk factors might help target emerging preventive strategies, for example, to individuals with a history of opioid use disorder, or might lead to new treatment approaches such as the use of tools to ameliorate depressed mood.

28 keywords...

hide…